Agus Sulistyono

New three-dimensional/four-dimensional volume rendering imaging software for detecting the abnormally invasive placenta

This study aimed to determine the role of three‐dimensional (3D)/four‐dimensional (4D) volume rendering ultrasound (VRU) in the diagnosis of abnormally invasive placenta (AIP).

Serum heme oxygenase 1 (HO-1), soluble FMS like tyrosine kinase (sFlt-1) level, and neonatal outcome in early onset, late onset preeclampsia, and normal pregnancy

ABSTRACT Objective: To compare the level of serum heme oxygenase 1 (HO-1), soluble FMS like tyrosine kinase (sFlt-1), and neonatal outcome in early onset preeclampsia (EO-PE), late onset preeclampsia (LO-PE), and normal pregnancy (NP). Methods: In this prospective observational case control study, HO-1 and sFlt-1 levels were measured in blood samples within 24 h of hospital admission. Preeclampsia cases were divided into two groups based on gestational age at delivery: EO-PE (<34 weeks) and LO-PE (≥34 weeks). A total of 45 patients were involved in this study. Result: Maternal serum level of sFlt-1 was higher in EO-PE than LO-PE and NP groups (mean ± SD; 14.50 ± 17.12 ng/ml vs 5.20 ± 6.69 ng/ml vs 2.72 ± 1.2 ng/ml [p = 0.020]. Maternal serum level of HO-1 was not different between EO-PE, LO-PE, and NP groups (p = 0.681). Birthweights were significantly lower in the EO-PE group compared with the LO-PE and NP groups (1580 ± 536 g vs 2635 ± 578 g vs 3010 ± 371 g [p = 0.000]). The rate of small for gestational age infant (26.7% vs 6.7% vs 0%; p = 0.046) and perinatal death (20% vs 0 vs 0; p = 0.037) was also significantly higher in EO-PE compared to LO-PE and NP. The maternal sFlt-1 level was negatively correlated with birthweight (p = 0.006; CC = −0.445). Conclusion: This study did not find a correlation between maternal HO-1 levels and sFlt-1 levels. Maternal serum sFLt-1 levels in preeclampsia were higher in EO-PE and were associated with a worse perinatal outcome.

P26. Comparison serum inhibin A level, placenta inhibin A level and placenta inhibin A expression in severe preeclampsia/eclampsia and normal pregnant women

in the year 2010 where 15 severe pre-eclampsia/eclampsia and 15 normal pregnant blood samples as control were collected. ELISA method was use to make assesment of inhibin A maternal serum and placental levels, for the expression of placental inhibin A, immunohistochemistry method was done in this study as well as the use of statistical analysis. Results: Inhibin A serum levels in both maternal and placental appeared to be significantly increase comparing with normal pregnancy as control as well as its expression in placenta. In severe pre-eclampsia/eclampsia they were found as 17.3 ± 12.9 ng, 18.1 ± 13.5 ng, 20.4 ± 5.2 ng, respectively at the levels of maternal serum, placental and placental expression compared to normal pregnancy as 5.3 ± 1.8 ng (p < 0.05), 6.2 ± 1.6 ng (p < 0.05) and 4.9 ± 1.6 ng (p < 0.05). Conclusion: Inhibin A increase seem in severe preeclampsia/eclampsia.